Global Fund

Company

Related News

Zimbabwe Launches Lenacapavir HIV Prevention Injection

Zimbabwe began rolling out lenacapavir, a twice-yearly injectable HIV prevention drug, on February 19 in Epworth. The program will initially target more than 46,000 people at high risk across 24 sites nationwide.

Related Clinical Trials

NCT ID Title Status Phase
NCT06076213

Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo

COMPLETED PHASE4
NCT04041973

Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)

COMPLETED NA
NCT03931473

Efficacy of Two Dual Active Ingredient Long Lasting Insecticidal Nets for Control of Malaria Transmitted by Pyrethroid Resistant Vectors in Benin

COMPLETED NA
NCT03249493

Monitoring Of Viral Load In Decentralised Area in Vietnam

COMPLETED
NCT03101852

Nutritional Rehabilitation in Senegalese HIV-infected Children and Adolescents

COMPLETED NA
NCT02238405

A Controlled Smoking Cessation Trial and Prospective Cohort Study of Tuberculosis (TB) Treatment Outcomes

COMPLETED NA
NCT00433030

Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand

COMPLETED
NCT00380146

Pharmacokinetics, Efficacy, Gametocyte Carriage, Birth Outcomes Following Sulfadoxine-pyrimethamine Intermittent Presumptive Treatment in Pregnant Women

COMPLETED NA
NCT00331708

Artesunate Plus Sulfadoxine-pyrimethamine Pharmacokinetics, Efficacy, Gametocytes Carriage and Birth Outcomes in Pregnant Women With Malaria

TERMINATED NA
NCT00203801

Combination Antimalarials in Uncomplicated Malaria

COMPLETED NA